Use of the basic form of recombinant human Erythropoietin in the treatment of patients with spinocerebellar ataxia type CAG Repeat Mutations

摘要

Use of pharmaceutical compositions that have Active principle is the basic form of recombinant human erythropoietin (rhEPO) and is administered by nasal spray in the treatment of ataxiaAtaxia (SCA) type CAG Repeat mutations, particularly the SCA Type 2.Method of Stratification of patients as responders or not to treatment with the basic form of rhEPO.Claim 1: Use of the basic form of recombinant human erythropoietin (rhEPO) to manufacture a Formulation for nasal Administration,Useful in the treatment of spinocerebellar ataxia (SCA) with mutations of Type CAG repeats.